BioNTech sends $70M to another ADC partner to go up against Daiichi Sankyo in HER3
First, HER2. Now, HER3. That’s the plan of attack for BioNTech in its apparent bid to follow in the footsteps of antibody-drug conjugate leader Daiichi Sankyo.
After licensing a HER2-targeting ADC from DualityBio in April and taking the treatment candidate into Phase III this fall, BioNTech is now teaming up with another China biotech, MediLink Therapeutics, to go after HER3.
The German biotech, flush with Covid-19 vaccine money, will dish out $70 million upfront to Suzhou-based MediLink just weeks after Daiichi Sankyo said it would seek the first HER3 ADC approval in the next few months as it builds on its HER2 Enhertu dominance with partner AstraZeneca. A BioNTech spokesperson declined to comment beyond the press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.